Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.62 |
| ▸ | LAP3 | P28838 | 2/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14330752 | 0.77 | FOLH1 (0.36) | FOLH1 | |
| SCHEMBL14330735 | 0.77 | FOLH1 (1.00) | FOLH1LAP3ANPEPGRM3NAALAD2 | |
| SCHEMBL2001657 | 0.77 | FOLH1 (1.00) | FOLH1LAP3ANPEPGRM3NAALAD2 | |
| SCHEMBL1995168 | 0.77 | FOLH1 (1.00) | FOLH1LAP3ANPEPGRM3NAALAD2 | |
| SCHEMBL2031866 | 0.77 | FOLH1 (1.00) | FOLH1LAP3ANPEPGRM3NAALAD2 | |
| SCHEMBL2032825 | 0.77 | FOLH1 (1.00) | FOLH1LAP3ANPEPGRM3NAALAD2 | |
| SCHEMBL1997642 | 0.77 | FOLH1 (1.00) | FOLH1LAP3ANPEPGRM3NAALAD2 | |
| SCHEMBL14330734 | 0.77 | FOLH1 (1.00) | FOLH1LAP3ANPEPGRM3NAALAD2 | |
| SCHEMBL14330757 | 0.77 | FOLH1 (1.00) | FOLH1LAP3ANPEPGRM3NAALAD2 | |
| SCHEMBL14330756 | 0.77 | FOLH1 (1.00) | FOLH1LAP3ANPEPGRM3NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | PIRAMAL IMAGING SA (CH) | 2012-12-27 | — | — | US | disclosed |
| EP-2513121-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | Piramal Imaging SA (CH) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012104225-A1 | DERIVATIZATION OF RADIOPHARMACEUTICALS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-09 | — | — | WO | disclosed |
| EP-2338892-A1 | Prostate specific membrane antigen inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-06-29 | — | — | EP | disclosed |
| WO-2011073286-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, ACP3 | FOLH1 2/4885LAP3 160/4885ANPEP 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.